Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Condylomata Acuminata 9Uterine Cervical Neoplasms 7Vulvar Neoplasms 2Vaginal Neoplasms 2Papillomavirus Infections 2Uterine Cervical Dysplasia 1Penile Neoplasms 1Anus Neoplasms 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Vaccines, Synthetic 2Radiotherapy 2nanocis 1Wound Closure Techniques 1Vaccines 1Technetium-99 1Suburethral Slings 1Radiation 1Papillomavirus Vaccines 1Octreotide 1Infracyanine green 1Indocyanine Green 1Fibrin Tissue Adhesive 1Fentanyl 1Dehydroepiandrosterone 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Vulvar Neoplasms × Vaccines, Synthetic × Clear all
NCT04422366 2024-06-07

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Shanghai Bovax Biotechnology Co., Ltd.

Phase 3 Recruiting
8,000 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT01245764 2018-11-14

GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Merck Sharp & Dohme LLC

Phase 3 Completed
250 enrolled 20 charts
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡